Prostate Cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Initial puncture pathology or postoperative pathology confirms GS 9-10 points. 2. Patients with radiological confirmation of distant metastases. 3. Treatment regimen: all-site radiotherapy + standard systemic therapy (ADT + novel hormonal therapy ± chemotherapy). The radiotherapy protocol includes: all-site radiotherapy targeting all metastatic lesions or all residual active disease following systemic therapy. 4. Expected survival exceeding 12 months. 5. Age >= 18 years. 6. KPS >= 80 points. 7. White blood cell count >= 3.5 × 10?/L, neutrophil count >= 1.5 × 10?/L, platelet count >= 100.0 × 10?/L, haemoglobin >= 90 g/L. 8. Informed consent of the subject.
Exclusion criteria
Exclusion criteria: 1. Previous history of malignant tumors (except for tumors that have been cured for more than 5 years). 2. Previous abdominal radiotherapy. 3. Weight loss exceeding 10% within the past six months. 4. Individuals with pre-existing or concomitant bleeding disorders. 5. Active infection. 6. Clinically evident cardiac disease (e.g., drug-resistant hypertension, unstable angina pectoris, congestive heart failure at New York Heart Association [NYHA] class >= II, unstable symptomatic arrhythmia, or peripheral vascular disease at >= NYHA class II). 7. Individuals unable to provide informed consent due to psychological, familial, or social factors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| radiographic progression-free survival;Overall Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Prostate Cancer-Specific Survival;PSA progression-free survival;Urinary symptom deterioration-free survival;Castration-Resistant Prostate Cancer-Free Survival;Prostate Cancer Treatment Function Assessment.;New anti-cancer treatment-free survival;Skeletal event-free survival; | — |
Countries
China
Contacts
Peking University First Hospital